The invention in a salt, solvate or hydrate (Formula I compound or a pharmaceutically acceptable thereof, medicaments of the formula I, ASC is -N (R8) (R9) ASC-1 and ASC-1 is the formula (ASC-1 ) will, ring a represents a 4-to 6-membered saturated ring containing carbon atoms as ring members in addition to the nitrogen atom, where one of the CH2 moiety in the ring a is optionally substituted by CH (R21), the one of the carbons in the ring a which is not adjacent to the nitrogen atom atom is optionally replaced by O, ring a is connected to X via a carbon atom, and X is a bond, -CH2- or -C (= O) - a It represents AR1, AR2 are independently phenyl, or O, S, represents a 5-or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from N, wherein AR1 is connected to L1 via a carbon atom and, AR2 is connected to the L1 and L2 through a carbon atom R1, R2 , R3 are independently hydrogen, halogen, cyano, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C3-C8-cycloalkyl, C1-C6 alkoxy, C1-C6-haloalkoxy, -C1-C6 alkylene- N (R12) R13, -N (R12) R13, C (O) OR11, -C (O) N (R12) R13, -S (O) represents OR11 or phenyl R4 is hydroxyl, hydrogen, halogen, by nitro, cyano, amino, one to five R14 to selectively alkenyl substituted C1-C6 alkyl, 1 to 5 R14 to an optionally substituted C2-C6 alkenyl by way, one to five R14 optionally, a C2-C6 alkynyl, one to five R14 to an optionally substituted C1-C6-alkoxy, one to five R14 to optionally substituted C2-C6 alkenyloxy substituted by, one to by 5-substituted optionally substituted C2-C6 alkynyloxy, -C (O) OR15, -CHO, -C (O) N (R16) R17, -C1-C6 alkylene -N (R9) by the two R14 (R16) R17, -O-, or -P cycle represents a cycle -O- -Q R5, R6, R7 are independently hydrogen, halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 represents a haloalkoxy R8 represents hydrogen, methyl or ASC-1 R9 is methyl or absent, wherein if R9 are present, and each nitrogen atom has a positive charge R10 represents hydrogen or methyl R11 is, independen
